ATE411045T1 - Modulatoren des p-selectin-glycoprotein-liganden 1 - Google Patents

Modulatoren des p-selectin-glycoprotein-liganden 1

Info

Publication number
ATE411045T1
ATE411045T1 AT02733839T AT02733839T ATE411045T1 AT E411045 T1 ATE411045 T1 AT E411045T1 AT 02733839 T AT02733839 T AT 02733839T AT 02733839 T AT02733839 T AT 02733839T AT E411045 T1 ATE411045 T1 AT E411045T1
Authority
AT
Austria
Prior art keywords
cell
selectin
modulators
glycoprotein ligand
induce
Prior art date
Application number
AT02733839T
Other languages
English (en)
Inventor
Rong-Hwa Lin
Chung-Hsiun Wu
Pei-Ling Hsu
Original Assignee
Abgenomics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abgenomics Corp filed Critical Abgenomics Corp
Application granted granted Critical
Publication of ATE411045T1 publication Critical patent/ATE411045T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
AT02733839T 2001-08-03 2002-03-13 Modulatoren des p-selectin-glycoprotein-liganden 1 ATE411045T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31019601P 2001-08-03 2001-08-03
US10/051,497 US7744888B2 (en) 2001-08-03 2002-01-18 Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies

Publications (1)

Publication Number Publication Date
ATE411045T1 true ATE411045T1 (de) 2008-10-15

Family

ID=26729479

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02733839T ATE411045T1 (de) 2001-08-03 2002-03-13 Modulatoren des p-selectin-glycoprotein-liganden 1
AT08012718T ATE531734T1 (de) 2001-08-03 2002-03-13 Antikörper gegen p-selectin-glycoproteinliganden 1 (psgl-1) zur behandlung allergischer erkrankungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT08012718T ATE531734T1 (de) 2001-08-03 2002-03-13 Antikörper gegen p-selectin-glycoproteinliganden 1 (psgl-1) zur behandlung allergischer erkrankungen

Country Status (20)

Country Link
US (3) US7744888B2 (de)
EP (2) EP1985634B1 (de)
JP (3) JP4815101B2 (de)
KR (1) KR100850731B1 (de)
CN (2) CN101045161B (de)
AT (2) ATE411045T1 (de)
AU (1) AU2002305041B2 (de)
CA (1) CA2428822C (de)
CY (2) CY1108701T1 (de)
DE (1) DE60229394D1 (de)
DK (2) DK1985634T3 (de)
ES (2) ES2316569T3 (de)
HK (2) HK1065489A1 (de)
IL (4) IL160168A0 (de)
MX (1) MXPA04001047A (de)
NO (2) NO333456B1 (de)
NZ (1) NZ531199A (de)
PT (2) PT1985634E (de)
TW (1) TWI327070B (de)
WO (1) WO2003013603A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7744888B2 (en) * 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) * 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
CA2538284C (en) * 2003-09-15 2015-10-20 Rong-Hwa Lin Modulators of p-selectin glycoprotein ligand 1
EP1689776A2 (de) * 2003-11-12 2006-08-16 Wisconsin Alumni Research Foundation Equiner p-selectin-glycoproteinligand-1 und anwendungen dafür
UY28886A1 (es) * 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
AU2012201999C1 (en) * 2004-05-10 2016-05-12 Abgenomics Cooperatief U.A. Antibodies
TWI446920B (zh) * 2004-05-11 2014-08-01 Abgenomics Cooperatief Ua Ｔ細胞之死亡誘導表位
WO2007033959A2 (en) * 2005-09-19 2007-03-29 Vib Vzw Use of p-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas
US20070160601A1 (en) * 2005-12-09 2007-07-12 Angela Widom Neutralizing antibodies against primate psgl-1 and uses therefor
CA2724415C (en) * 2008-05-15 2016-09-13 Selexys Pharmaceuticals Corporation Anti-psgl-1 antibodies and methods of identification and use
ES2387156B1 (es) * 2010-12-01 2013-07-04 Universidad Autónoma de Madrid Uso de psgl-1 para el tratamiento de enfermedades inflamatorias y autoinmunes
WO2012174001A1 (en) 2011-06-13 2012-12-20 Abgenomics Cooperatief U.A. Anti-psgl-1 antibodies and uses thereof
CA2953706A1 (en) * 2014-07-08 2016-01-14 Sanford-Burnham Medical Research Institute Psgl-1 modulators and uses thereof
CN108713026B (zh) 2016-01-08 2023-01-06 美国全心医药生技股份有限公司 四价抗psgl-1抗体及其用途
US20170241415A1 (en) * 2016-02-19 2017-08-24 Muzan, Inc. Sanitary check valve
WO2018132476A1 (en) 2017-01-11 2018-07-19 Bristol-Myers Squibb Company Psgl-1 antagonists and uses thereof
CN110740749A (zh) 2017-03-14 2020-01-31 戊瑞治疗有限公司 在酸性pH下与VISTA结合的抗体
CA3106418A1 (en) 2018-07-20 2020-01-23 Pierre Fabre Medicament Receptor for vista
WO2020224450A1 (en) * 2019-05-03 2020-11-12 The University Of Hong Kong Method for peritoneal metastatic cell detection and isolation thereof
CA3141334A1 (en) * 2019-06-04 2020-12-10 Verseau Therapeutics, Inc. Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5378464A (en) * 1989-03-08 1995-01-03 Board Of Regents Of The University Of Oklahoma Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
US5464778A (en) * 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5709859A (en) * 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US6124267A (en) * 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US6309639B1 (en) * 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US5972625A (en) * 1991-05-06 1999-10-26 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
WO1994014836A1 (en) * 1992-12-18 1994-07-07 Centocor, Inc. Peptide inhibitors of selectin binding
SG48892A1 (en) * 1993-01-25 1998-05-18 Dana Faber Cancer Inst Inc Chimeric L- and P-selectin by exchange of domains-uses thereof
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
US5686426A (en) 1994-11-17 1997-11-11 Bristol-Myers Squibb Company Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors
ES2208759T3 (es) 1995-08-03 2004-06-16 Board Of Regents Of The University Of Oklahoma O-glicanos inhibidores de la inflamacion mediada por selectina.
JPH09227410A (ja) 1996-02-21 1997-09-02 Sumitomo Pharmaceut Co Ltd 臓器移植拒絶反応の抑制剤
WO1999043353A2 (en) * 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
NZ528610A (en) 1998-10-30 2005-03-24 Inst Genetics Llc Inhibition of differentiation of cytotoxic T-cells by P-selectin ligand (PSGL) antagonists
IL156689A0 (en) 2000-12-29 2004-01-04 Savient Pharmaceuticals Inc Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040002450A1 (en) * 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) * 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US20050152906A1 (en) * 2003-06-30 2005-07-14 Avigdor Levanon Specific human antibodies
UY28886A1 (es) 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
TWI446920B (zh) 2004-05-11 2014-08-01 Abgenomics Cooperatief Ua Ｔ細胞之死亡誘導表位
WO2012174001A1 (en) 2011-06-13 2012-12-20 Abgenomics Cooperatief U.A. Anti-psgl-1 antibodies and uses thereof

Also Published As

Publication number Publication date
US8298540B2 (en) 2012-10-30
NO334850B1 (no) 2014-06-16
JP2008260759A (ja) 2008-10-30
WO2003013603A1 (en) 2003-02-20
AU2002305041B2 (en) 2005-11-10
CN101045161A (zh) 2007-10-03
KR100850731B1 (ko) 2008-08-06
NO20040460L (no) 2004-02-24
US20030049252A1 (en) 2003-03-13
JP2012092144A (ja) 2012-05-17
TWI327070B (en) 2010-07-11
IL160168A0 (en) 2004-07-25
ES2316569T3 (es) 2009-04-16
WO2003013603A8 (en) 2004-06-10
US8557579B2 (en) 2013-10-15
ATE531734T1 (de) 2011-11-15
DE60229394D1 (en) 2008-11-27
DK1411982T3 (da) 2009-02-16
CA2428822C (en) 2014-10-28
US20090304709A1 (en) 2009-12-10
PT1411982E (pt) 2008-12-24
EP1985634A1 (de) 2008-10-29
DK1985634T3 (da) 2012-02-20
EP1985634B1 (de) 2011-11-02
CN1304051C (zh) 2007-03-14
IL204030A0 (en) 2011-08-01
NO333456B1 (no) 2013-06-10
EP1411982B1 (de) 2008-10-15
HK1065489A1 (en) 2005-02-25
NO20130069L (no) 2004-02-24
IL204030A (en) 2014-11-30
US7744888B2 (en) 2010-06-29
CN101045161B (zh) 2010-06-16
US20130011861A1 (en) 2013-01-10
IL210557A0 (en) 2011-03-31
EP1411982A1 (de) 2004-04-28
EP1411982A4 (de) 2004-10-06
IL160168A (en) 2011-02-28
CN1473052A (zh) 2004-02-04
JP4815101B2 (ja) 2011-11-16
NZ531199A (en) 2004-11-26
PT1985634E (pt) 2012-02-07
CY1112966T1 (el) 2016-04-13
HK1124624A1 (en) 2009-07-17
CA2428822A1 (en) 2003-02-20
KR20040054670A (ko) 2004-06-25
JP2004521958A (ja) 2004-07-22
MXPA04001047A (es) 2005-02-17
CY1108701T1 (el) 2014-04-09
ES2376948T3 (es) 2012-03-21

Similar Documents

Publication Publication Date Title
IL204030A0 (en) Modulators of p-selectin glycoprotein ligand 1
WO2005027831A3 (en) Modulators of p-selectin glycoprotein ligand 1
SG155205A1 (en) Interleukin-10 antibodies
DE69736995D1 (de) Kristallisierbare Zusammensetzungen, die einen Komplex von Protease-Domäne NS3 und NS4A aus dem Hepatitis C Virus enthalten, und damit bereitgestellte Kristalle
HK1034040A1 (en) Apo-2 ligand-anti-her-2 antibody synergism
NO20060189L (no) Antistoffer mot interleukin-22 og anvendelse derav
DK1226233T3 (da) Multipotente voksne stamceller og fremgangsmåder til isolering heraf
DE69007823D1 (de) Behandeltes Siliziumdioxid zur Verstärkung von Silikonelastomer.
PL339744A1 (en) Azabenzimidazole based compounds useful in modulating action of serinic/treoninoic proteinic kinase
ATE471334T1 (de) Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs
ATE238047T1 (de) Verwendung von n,n-bis (phenylcarbamoylmethyl) dimethylammoniumchlorid und derivaten davon zur behandlung von chronischem schmerz
AU2001293777A1 (en) Support device for a preparation for the separation of individual objects from the preparation by means of laser irradiation
TW200513262A (en) Modulators of P-selectin glycoprotein ligand 1
AU2002364302A8 (en) Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
DE602004032135D1 (de) Materialien und verfahren zur verarbeitung von nichtwässrigen gemischen
DK0568379T3 (da) Sammensætninger og fremgangsmåde til befugtning af partikler
DK1241094T3 (da) Forsænket lys til færdselsflader, f.eks. i lufthavne
SE8305444D0 (sv) Bakterieavvisande ytor
DE602004025577D1 (de) Ungen und verfahren zu deren herstellung
ATE309808T1 (de) Ex vivo behandlung von allogenen und xenogenen t- zellen mit gp39-antagonisten
Hernandez Contribution to the biology of Neritina virginea(Mollusca: Gastropoda) in communities of Ruppia maritima L., at the lagoon system of Alvarado, Veracruz, Mexico.
Peñuelas Biosphere, evolution, brains, and sex: Reflections about biology and ecology.
Van Cleave Plato and Jesus (Philo of Alexandria)
RU2004113381A (ru) Самонастраивающееся устройство восстановления природных свойств биообъектов
IT8921715V0 (it) Struttura di portacandela, particolarmente per realizzare composizioni floreali e simili.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1411982

Country of ref document: EP